tirzepatide isn't working Why Semaglutide or for Me? Why Am I Not Losing

Description

Patients should be counseled to contact their healthcare provider if they experience any of the following: Severe or persistent gastrointestinal symptoms including intractable nausea or vomiting lasting more than 24-48 hours, inability to maintain adequate oral hydration, severe abdominal pain (particularly if localized to the upper abdomen or radiating to the back), or signs of gastrointestinal bleeding such as bloody or black stools

Foundayo (orforglipron) is another oral GLP-1 option, offering flexibility, as it can be taken anytime without food or drink restrictions

If you believe tirzepatide is not providing the expected benefits, do not discontinue treatment without consulting your healthcare provider

Special Populations Requiring Monitoring : Elderly patients may be more susceptible to gastrointestinal side effects and dehydration Patients taking insulin or sulfonylureas require dose adjustments of these medications to prevent hypoglycemia Patients with cardiovascular disease should be monitored, though cardiovascular outcomes data are still emerging Patients with depression or suicidal ideation (particularly for Zepbound) require careful monitoring for worsening symptoms Pediatric patients : Safety and efficacy have not been established in patients under 18 years of age Regarding renal function, no dose adjustment is required for patients with renal impairment, including those with end-stage renal disease